Trial Profile

A Phase IIb, Randomized, Open-labeled Trial to Evaluate the Immunogenicity and Safety of One or Two Doses of Booster Vaccine With the COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain in Adults in Hong Kong

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Sep 2023 Status changed from recruiting to completed.
04 Jul 2022 According to a Sinovac Biotech media release, the Omicron strain booster immunization clinical trial was approved by the HKU GHK Institutional Review Board (IRB) on 12th April 22 and by the Pharmacy and Poisons Board of Hong Kong on 14th April 22.
04 Jul 2022 According to a Sinovac Biotech media release, company joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off this trial.This study is led by a medical research team of the University of Hong Kong Clinical Trials Centre (HKU-CTC) in collaboration with Gleneagles

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com